Compare GE Vernova Inc (GEV) vs Medpace Holdings Inc (MEDP) Price & Performance

GE Vernova (GEV) trades at $1,039.90, up 4.95% in the last session, supported by strong technical momentum and bullish analyst sentiment. The company reported mixed Q2 2026 earnings with a miss on EPS expectations but maintains robust revenue growth and a massive $176 billion backlog. Valuation metrics remain elevated with a P/E of 29.01 and EV/EBITDA of 86.33, reflecting high growth expectations tied to AI-driven power demand.

Outlook remains positive given GEV's strategic positioning in AI infrastructure and energy transition, though premium valuation and execution risks on backlog conversion warrant caution. Strong institutional support with 76% buy ratings and consensus price target of $1,270 suggests upside potential, but investors should monitor quarterly execution against high expectations.

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.